Skip to main content
Journal cover image

Immune checkpoint blockade: Releasing the brake towards hematological malignancies.

Publication ,  Journal Article
Xia, Y; Medeiros, LJ; Young, KH
Published in: Blood Rev
May 2016

Tumor cells utilize co-inhibitory molecules to avoid host immune destruction. Checkpoint blockade has emerged as a promising approach to treat cancer by restoring T cell effector function and breaking a tumor permissive microenvironment. Patients with hematological malignancies often have immune dysregulation, thus the role of checkpoint blockade in treatment of these neoplasms is particularly intriguing. In early trials, antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) or the programmed death 1 (PD-1) signaling pathway have displayed significant efficacy with minimal toxicity in patients with relapsed and refractory hematological neoplasms. In this review, we provide evidence of dysregulation of CTLA-4 and PD-1/PD-Ls in the context of several major types of hematological neoplasms and summarize relevant clinical practice points for checkpoint blockade. The preclinical rationale and preliminary clinical data of potential combination approaches designed to optimize checkpoint antagonists are well presented.

Duke Scholars

Published In

Blood Rev

DOI

EISSN

1532-1681

Publication Date

May 2016

Volume

30

Issue

3

Start / End Page

189 / 200

Location

England

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Signal Transduction
  • Programmed Cell Death 1 Receptor
  • Programmed Cell Death 1 Ligand 2 Protein
  • Molecular Targeted Therapy
  • Immunomodulation
  • Immunology
  • Humans
  • Hematologic Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xia, Y., Medeiros, L. J., & Young, K. H. (2016). Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev, 30(3), 189–200. https://doi.org/10.1016/j.blre.2015.11.003
Xia, Yi, L Jeffrey Medeiros, and Ken H. Young. “Immune checkpoint blockade: Releasing the brake towards hematological malignancies.Blood Rev 30, no. 3 (May 2016): 189–200. https://doi.org/10.1016/j.blre.2015.11.003.
Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016 May;30(3):189–200.
Xia, Yi, et al. “Immune checkpoint blockade: Releasing the brake towards hematological malignancies.Blood Rev, vol. 30, no. 3, May 2016, pp. 189–200. Pubmed, doi:10.1016/j.blre.2015.11.003.
Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016 May;30(3):189–200.
Journal cover image

Published In

Blood Rev

DOI

EISSN

1532-1681

Publication Date

May 2016

Volume

30

Issue

3

Start / End Page

189 / 200

Location

England

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Signal Transduction
  • Programmed Cell Death 1 Receptor
  • Programmed Cell Death 1 Ligand 2 Protein
  • Molecular Targeted Therapy
  • Immunomodulation
  • Immunology
  • Humans
  • Hematologic Neoplasms